Prothrombin Complex Concentrates for Warfarin Reversal Before Heart Transplantation

Area of Science:

• Cardiology
• Transplantation Medicine
• Hematology

Background:

• Warfarin anticoagulation is standard before heart transplantation, posing perioperative management challenges.
• Effective warfarin reversal is crucial for optimizing surgical outcomes in transplant recipients.

Purpose of the Study:

• To evaluate the impact of a prothrombin complex concentrate (PCC)-based warfarin reversal protocol on perioperative outcomes in heart transplant patients.
• To compare blood product utilization and clinical outcomes before and after implementing a PCC protocol.

Main Methods:

• A retrospective cohort study compared heart transplant patients who received PCC for warfarin reversal (PCC cohort) with historical controls.
• International Normalized Ratio (INR) > 1.5 was the threshold for PCC administration.
• Coprimary endpoints included fresh frozen plasma, packed red blood cells, and platelet utilization; secondary endpoints covered mortality, reoperation, and length of stay.

Main Results:

• The PCC cohort (n=57) showed a significant reduction in fresh frozen plasma use compared to controls (n=49).
• Cryoprecipitate utilization increased in the PCC cohort, potentially due to reduced antifibrinolytic use.
• No significant differences were observed in packed red blood cells, platelet transfusion, thromboembolic events, or other secondary outcomes.

Conclusions:

• A PCC-based warfarin reversal protocol effectively reduces fresh frozen plasma utilization in heart transplant patients.
• PCC serves as a valuable tool for INR normalization, offering a safe and practical alternative to traditional methods.
• The protocol did not negatively affect critical surgical outcomes or increase thrombotic risk.